Currently, there are 145.98M common shares owned by the public and among those 141.29M shares have been available to trade.
The company’s stock has a 5-day price change of 15.77% and -20.09% over the past three months. ETNB shares are trading 15.47% year to date (YTD), with the 12-month market performance up to 0.67% higher. It has a 12-month low price of $4.16 and touched a high of $11.84 over the same period. ETNB has an average intraday trading volume of 1.87 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.72%, 21.66%, and 10.29% respectively.
Institutional ownership of 89bio Inc (NASDAQ: ETNB) shares accounts for 105.91% of the company’s 145.98M shares outstanding.
It has a market capitalization of $1.32B and a beta (3y monthly) value of 1.40. The earnings-per-share (ttm) stands at -$3.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.79% over the week and 8.11% over the month.
Analysts forecast that 89bio Inc (ETNB) will achieve an EPS of -0.46 for the current quarter, -0.5 for the next quarter and -2.16 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.52 while analysts give the company a high EPS estimate of -0.52. Comparatively, EPS for the current quarter was -0.48 a year ago. Earnings per share for the fiscal year are expected to increase by 41.04%, and -4.18% over the next financial year. EPS should shrink at an annualized rate of 16.04% over the next five years, compared to 32.21% over the past 5-year period.
Looking at the support for the ETNB, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on March 14, 2025, with the firm’s price target at $11. Citigroup coverage for the 89bio Inc (ETNB) stock in a research note released on March 13, 2025 offered a Buy rating with a price target of $25. Wolfe Research was of a view on February 04, 2025 that the stock is Outperform, while BofA Securities gave the stock Buy rating on April 22, 2024, issuing a price target of $30. RBC Capital Mkts on their part issued Sector Perform rating on January 12, 2024.
